OGT to hold live webinar on NGS and data analysis strategies for cancer research

  • Email
  • Print

Optimising next generation DNA and RNA sequencing studies

Oxford, UK – 15 January 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine will hold a live webinar entitled ‘Effective cancer sequencing and analysis strategies’ on Thursday 31st January 2013 at 3:00pm (GMT). Dr Simon Hughes, Team Leader Cancer R&D, OGT and Dr Daniel Swan, Senior NGS Computational Biologist, OGT will discuss next generation DNA and RNA sequencing for cancer research studies including choosing the best sequencing strategy, experimental design for targeted resequencing, types of samples, and the use of OGT’s NGS browser for the effective and rapid identification of genetic aberrations such as copy number variation, loss of heterozygosity and splice variants.

Next generation DNA and RNA sequencing is providing previously unattainable insight into disease development, progression and treatment of cancer. However, it is still a challenge to implement efficient sequencing and data analysis strategies to identify genomic aberrations and relevant mutations. The webinar will provide insight into running effective sequencing projects and data analysis using OGT’s Genefficiency™ Cancer Sequencing Service which offers researchers rapid high-quality, meaningful results from tumour cell populations. The webinar will be ideal for clinical researchers or anyone interested in learning about how to use the power of next generation sequencing to study genetic variation in mixed cell populations.

To register for the webinar please visit the sign-up page. For more information about OGT’s Cancer Sequencing Service and other genomic services, go to www.ogt.com.

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine.  The company has two trading businesses: Genomic Solutions comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Diagnostic Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.

CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures

CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T:+44 (0) 1865 856826; F: +44 (0) 1865 848684; E: contact@ogt.com

W: www.ogt.com ; Twitter: @OxfordGeneTech

  • <<
  • >>